Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Danish Therapeutics company focused on antibody-drug conjugates (ADCs) for the treatment of cancers.
ADCs are a class of highly potent biopharmaceutical drugs, composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. ADCs combine the unique and very sensitive targeting capabilities of antibodies, with the potent effects of the conjugated cytotoxic drugs, allowing sensitive discrimination between healthy and cancer tissues. ADCendo raised a €51 million ($62 million) Series A financing to establish a pipeline of ADCs directed at novel cancer targets and to bring the lead program targeting the novel cancer target uPARAP/Endo180 to proof of concept in soft tissue sarcoma patients.
More ADCendo news
Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01
Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline
Gilde Healthcare company ADCendo appoints Dominik Mumberg, PHD, as Chief Scientific Officer
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
Gilde Healthcare portfolio company ADCendo appoints Michael Pehl as Chief Executive Officer
Gilde Healthcare participates in €51M series A financing of Danish biopharmaceutical start-up ADCendo
Argá Medtech
Argá Medtech is developing the next generation non-thermal cardiac ablation system. The system for treating...
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated...
CVRx
US-based MedTech company focused on treatment of heart failure applying neurostimulation.